Sec Form 4 Filing - Cooperatieve Gilde Healthcare IV U.A. @ LAVA Therapeutics NV - 2025-10-08

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Cooperatieve Gilde Healthcare IV U.A. 2. Issuer Name and Ticker or Trading Symbol LAVA Therapeutics NV [ LVTX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) STADSPLATEAU 36 3. Date of Earliest Transaction (MM/DD/YY) 10/08/2025 (Street) UTRECHT, P73521 AZ 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 10/08/2025 S 28,954 D $ 1.57 ( 1 ) 5,392,216 D ( 2 ) Common Shares 10/09/2025 S 48,169 D $ 1.56 ( 3 ) 5,344,047 D ( 2 ) Common Shares 10/10/2025 S 49,869 D $ 1.55 ( 4 ) 5,294,178 D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Cooperatieve Gilde Healthcare IV U.A. STADSPLATEAU 36 UTRECHT, P73521 AZ X Gilde Healthcare Holding B.V. STADSPLATEAU 36 UTRECHT, P73521 AZ X Signatures Cooperatieve Gilde Healthcare IV U.A., By: /s/ Edwin de Graaf, Managing Director 10/10/2025 Signature of Reporting Person Date Gilde Healthcare IV Management B.V., By: /s/ Edwin de Graaf, Managing Director 10/10/2025 Signature of Reporting Person Date Gilde Healthcare Holding B.V., By: /s/ Edwin de Graaf, Managing Director 10/10/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This figure is the weighted average sales price of multiple trades ranging from $1.56 to $1.62 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request. ( 2 )The shares are held directly by Cooperatieve Gilde Healthcare IV U.A. ("Gilde Healthcare"). Gilde Healthcare IV Management BV ("GHCIVM") manages and advises Gilde Healthcare and is owned by Gilde Healthcare Holding BV ("GHH"). Each of GHCIVM and GHH disclaims beneficial ownership of the shares held by Gilde Healthcare, except to the extent of its respective pecuniary interests therein. ( 3 )This figure is the weighted average sales price of multiple trades ranging from $1.54 to $1.59 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request. ( 4 )This figure is the weighted average sales price of multiple trades ranging from $1.53 to $1.58 per share. The Reporting Person undertakes to provide the Staff of the Securities and Exchange Commission, LAVA Therapeutics NV or any security holder of LAVA Therapeutics NV full information about the number of shares sold at each separate price upon request.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.